Clinical Trial Update: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole [Phase 2]

View source ↗

Summary

Phase II trial of lenvatinib and pembrolizumab with letrozole in endocrine-resistant, hormone receptor-positive, HER2-negative advanced breast cancer; currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer | Phase 2 | Status: RECRUITING